Results 1 to 10 of about 1,468,006 (309)
Combination Cancer Therapy and Reference Models for Assessing Drug Synergy in Glioblastoma [PDF]
Current OncologyGlioblastoma is currently an incurable disease despite the development of a wide variety of therapeutic approaches, from surgical methods to immunotherapy.
Semyon A. Sinyavskiy +4 more
doaj +2 more sources
Customising the therapeutic response of signalling networks to promote antitumor responses by drug combinations [PDF]
Frontiers in Oncology, 2014 Drug resistance, de novo and acquired, pervades cellular signalling networks from one signalling motif to another as a result of cancer progression and/or drug intervention.
Alexey eGoltsov +4 more
doaj +7 more sources
Editorial: Innovative drug combinations for enhanced solid tumor treatment efficacy [PDF]
Frontiers in OncologyGiovanna Damia, Massimo Broggini
doaj +2 more sources
Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus [PDF]
Diabetes & Metabolism Journal, 2021 We assessed the glycaemic durability with early combination (EC; vildagliptin+metformin [MET], n=22) versus MET monotherapy (n=17), among newly-diagnosed type 2 diabetes mellitus (T2DM) enrolled (between 2012 and 2014) in the VERIFY study from Korea (n ...
Soon-Jib Yoo +8 more
doaj +1 more source
Omadacycline Potentiates Clarithromycin Activity Against Mycobacterium abscessus
Frontiers in Pharmacology, 2021 Mycobacterium abscessus is a difficult respiratory pathogen to treat, when compared to other nontuberculus mycobacteria (NTM), due to its drug resistance.
Bui Thi Bich Hanh +7 more
doaj +1 more source
Basic principles of combination therapy: focus on drug-drug interaction
Кардиоваскулярная терапия и профилактика, 2021 The article is devoted to the issue of drug interactions in the combination regimens. Today, when drug therapy is the first-line approach for patients with noncommunicable diseases, and the world population ageing leads to an increase in the number of ...
S. Yu. Martsevich +2 more
doaj +1 more source
Exploratory Research in Clinical and Social Pharmacy, 2021 Background: Drug interactions are important causes of adverse events. Assessments of pharmacological interactions outside healthcare services settings are scarce. Objective: To assess the frequency and factors associated with these potential interactions
Tayanny Margarida Menezes Almeida Biase +2 more
doaj +1 more source
MedComm – Biomaterials and Applications, 2023 Various nanocarriers have been explored to deliver drugs for combination therapy. However, most nanocarriers are composed of inert materials without contribution for improving the cancer therapeutic effect.
Jingqi Xin +3 more
doaj +1 more source
Understanding and targeting resistance mechanisms in cancer
MedComm, 2023 Resistance to cancer therapies has been a commonly observed phenomenon in clinical practice, which is one of the major causes of treatment failure and poor patient survival. The reduced responsiveness of cancer cells is a multifaceted phenomenon that can
Zi‐Ning Lei +6 more
doaj +1 more source
Nanoparticles for Combination Drug Therapy [PDF]
ACS Nano, 2013 Nanoparticles have recently emerged as a promising class of carriers for the co-delivery of multiple drugs. Combination therapies of small-molecule drugs are common in clinical practice, and it is anticipated that packaging into single macromolecular carriers will enable drug release in precisely balanced ratios and rates and in selectively targeted ...
Liang, Ma, Manish, Kohli, Andrew, Smith
openaire +2 more sources